WO2007136672A2 - Synthesis of a biaryl synthetic intermediate - Google Patents

Synthesis of a biaryl synthetic intermediate Download PDF

Info

Publication number
WO2007136672A2
WO2007136672A2 PCT/US2007/011777 US2007011777W WO2007136672A2 WO 2007136672 A2 WO2007136672 A2 WO 2007136672A2 US 2007011777 W US2007011777 W US 2007011777W WO 2007136672 A2 WO2007136672 A2 WO 2007136672A2
Authority
WO
WIPO (PCT)
Prior art keywords
biaryl
reaction mixture
water
added
reaction
Prior art date
Application number
PCT/US2007/011777
Other languages
French (fr)
Other versions
WO2007136672A3 (en
Inventor
Remy Angelaud
Paul O'shea
Stephane Ouellet
Amelie Roy
Original Assignee
Merck & Co., Inc.
Merck Frosst Canada Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc., Merck Frosst Canada Ltd. filed Critical Merck & Co., Inc.
Publication of WO2007136672A2 publication Critical patent/WO2007136672A2/en
Publication of WO2007136672A3 publication Critical patent/WO2007136672A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01Preparation of ethers
    • C07C41/18Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/26Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01Preparation of ethers
    • C07C41/16Preparation of ethers by reaction of esters of mineral or organic acids with hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01Preparation of ethers
    • C07C41/18Preparation of ethers by reactions not forming ether-oxygen bonds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01Preparation of ethers
    • C07C41/18Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/22Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of halogens; by substitution of halogen atoms by other halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01Preparation of ethers
    • C07C41/18Preparation of ethers by reactions not forming ether-oxygen bonds
    • C07C41/30Preparation of ethers by reactions not forming ether-oxygen bonds by increasing the number of carbon atoms, e.g. by oligomerisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/225Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups

Definitions

  • This invention relates to a chemical process for making a pharmaceutically active compound, and specifically to a process for making a biaryl intermediate in the process for making the compound.
  • Biaryl chloride 10 is one of two penultimate intermediates in a process for making a pharmaceutically active compound.
  • Biaryl chloride 10 is prepared in a seven step sequence starting from available starting materials. One of the intermediates in the 7-step sequence is prepared in one step, so that the overall preparation of biaryl chloride 10 requires 8 process steps starting from commercially available difluorobromobenzene 1 and trifluoromethylbenzonitrile 6.
  • the Example below is provided to illustrate the invention, and should not be construed as limiting the invention.
  • the scope of the invention is defined by the Claims.
  • the product of this invention is a useful synthetic intermediate for making certain CETP inhibitors, such as those described in PCT patent applications WO2007/005572 (published after the priority date of this application), WO2006/014413, and WO2006/014357.
  • Methoxylation of bromodifluorobenzene 1 is highly regioselective when THF is the solvent. Using the conditions described below, the reaction typically yields an 18/1 ratio of product 2 along with 0.7A% (Assay%) of a dimethoxylated impurity. Other combinations of solvent and temperature and other methoxide salts may also be suitable in this sequence.
  • a 5OL round bottom flask (RBF) equipped with an overhead stirrer, a nitrogen inlet, a temperature probe and a condenser was charged with l-bromo-2,4-difluorobenzene 1 (3780 g) followed by THF (14 L) and KOMe (95 wt%, 1587.6g), and then rinsed with 1.1 L of THF.
  • the reaction mixture was heated to 65 - 68 0 C over 30 minutes and stirred at that temperature for 4 hr.
  • a second portion of KOMe was then added (144.4 g), and the reaction was stirred for an additional 2 hr.
  • the reaction mixture was cooled to 15 0 C and was transferred into a 50 L extractor containing 13.1 L of water.
  • the reaction flask was rinsed with water (2 L) and methyl t-butyl ether (MTBE) (15 L). The layers were cut and the organic layer was washed twice with water (2 x 15 L). The organic layer was concentrated under vacuum (10-20 mmHg, 30 0 C) followed by azeotropic removal of water with THF (8 L) (10-20 mmHg, 30 0 C). The crude residue was distilled under reduced pressure (90 0 C, 3 torr) to yield anisole 2 as a colorless oil.
  • MTBE methyl t-butyl ether
  • the batch was transferred into a 100 L extractor containing H 2 O (25 L) and
  • the organic layer was then transferred through an inline filter (PolycapTM 75 HD, Whatman Inc.) into a 50 L RBF and concentrated under vacuum (30 mmHg, 30 0 C) to a final volume of ⁇ 1 IL, and the solvent was switched to hexanes (74 L) at this volume. The resulting suspension was stirred —30 min at room temperature and 45 min at 0 0 C.
  • an inline filter PolycapTM 75 HD, Whatman Inc.
  • the slurry was filtered through a filter pot, and the solid obtained was washed with cold hexanes (0 0 C, 10 L) The solid was dried overnight under vacuum and a nitrogen sweep to give acetophenone 3 as white needles.
  • the batch was transferred into a 100 L extractor containing 16.8 Kg of saturated NaHCCh, stirred for 5 min, and the layers were cut. The bottom organic layer was washed twice with saturated NaHCCh, stirred for 5 min, and the layers were cut. The bottom organic layer was washed twice with saturated NaHCCh, stirred for 5 min, and the layers were cut. The bottom organic layer was washed twice with saturated NaHCCh, stirred for 5 min, and the layers were cut. The bottom organic layer was washed twice with saturated
  • a 2OL RBF equipped with an overhead stirrer, a nitrogen inlet, a temperature probe and a condenser was charged with the benzonitrile 6 (3930 g), followed by ethanolamine (3041 mL), CaCl 2 (382.4 g) and xylenes (1965 mL).
  • the reaction mixture was heated to 125 0 C over 45 min and stirred at this temperature for 17 hr. Then the reaction mixture was allowed to cool to about 80 0 C, and toluene (1965 mL) was added before cooling the reaction mixture to room temperature.
  • the crude reaction mixture was then transferred into a 100 L extractor containing 39 L of 0.1 M KH 2 PO 4 .
  • the reaction flask was rinsed with MTBE (8 L) and water (4 L). Heptane (28 L) was added to the extractor and the layers were cut. The aqueous layer was back extracted with a mixture of MTBE (10 L) and heptane (10 L), and then the combined organic layers were washed twice with water (2 x 20 L). The organic was concentrated under vacuum (35 0 C to 70 0 C, 30-5 mmHg). The crude residue was distilled under reduced pressure (110 0 C at 1 - 3 torr) to yield oxazoline 7 as a colorless oil.
  • the ruthenium-catalyzed CH-activation cross-coupling reaction described below gives a good yield of product using NMP (N-methyl pyrrol idinone) as solvent. It has been observed that as the amount of catalyst is reduced to less than 1 mole%, the reaction proceeds reproducibly only with NMP that contains greater than 0.5 volume% of gamma-butyrolactone impurity.
  • a 50L RBF equipped with an overhead stirrer, a nitrogen inlet and a temperature probe was charged with oxazoline 7 (2755.5 g) followed by anisole 5 (3065.7 g) and NMP (10 L pre- degassed by bubbling nitrogen for 60 min). The reaction after mixing was degassed by bubbling nitrogen for an additional 30 minutes. Then K 3 PO4 (4842.1 g) and KOAc (112.5 g) were charged, followed by 2 L of degassed NMP (rinse). This suspension was degassed for an additional 60 minutes. The reaction mixture was then heated to 130 0 C.
  • a 5L RBF was charged with degassed NMP (2 L) and triphenylphosphine (29.92 g), and then was degassed by bubbling nitrogen for 30 minutes at rt.
  • the ruthenium complex dimer (28.5 g) was then added, and this solution was degassed for an additional 30 minutes at rt.
  • Oxazoline activation/reduction is a 2-step one-pot process. Activation of biaryl oxazoline 8 with methyl chloroformate leads to the activated intermediate 9a, which is subsequently reduced to alcohol 9 by using sodium borohydride in water (Scheme T). The reduction can also be done with lithium borohydride with MeOH as solvent, and also with other borohydride reducing agents.
  • the amount of residual KF from earlier steps has to be below 500ppm before addition of methyl chloroformate.
  • the reaction mixture was cooled to 0°C, and 3.1N HCl (9.8 L) was added dropwise over Ih while maintaining the temperature between 0 and 4°C.
  • the reaction mixture was warmed to rt, and MeOH (7.8 L) was added.
  • the mixture was batch concentrated under reduced pressure (20 ramHg, 25°C) to a volume of 24 L.
  • MeOH (15.5 L) was added, and the batch was seeded with crystalline product from earlier batches (97 g). The product crystallizes spontaneously, if seed crystals are not available.
  • the slurry was aged at rt for Ih, and water (20 L) was added slowly over 1 h.
  • the slurry was filtered through a filter pot, and the cake was rinsed with MeOH/water (1 : 1 , 8 L) followed by water (16 L).
  • the cake was dried under vacuum at rt with nitrogen sweep over 2 days to give crude biaryl alcohol.
  • a IOOL RBF equipped with an overhead stirrer, a nitrogen inlet and a temperature probe was charged with crude 92 wt% biaryl alcohol 9 (3637.23g), MTBE (23.4 L), heptane (10 L) and finally DARCO KB-G (1673 g).
  • the slurry was stirred at rt for 2h.
  • DARCO was then removed by filtration on a pad of solka-floc and rinsed with MTBE/heptane (70:30, 39 L).
  • the combined filtrates were batch concentrated into a IOOL RBF under reduced pressure (20 mitiHg, 40°C) to a final volume of 3OL, and solvent was switched to heptane (66 L).
  • the resulting slurry was aged overnight at rt and was then cooled to -15 ⁇ C for 2h.
  • the slurry was filtered through a filter pot and the cake was washed with cold heptane (-15"C, 20L).
  • the cake was dried under vacuum with nitrogen overnight at rt to give pure biaryl alcohol 9 as a white powder with a residual Ru content of 25 ppm.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

An efficient process for manufacturing a biphenyl chloride chemical intermediate is disclosed. The biphenyl chloride is a synthetic intermediate for manufacturing a chemical compound which is a CETP inhibitor. The process comprises a CH activation step in which a phenyl bromide is coupled to the phenyl ring of a phenyl oxazoline to make a biphenyl structure.

Description

TITLE OF THE INVENTION
SYNTHESIS OF A BIARYL SYNTHETIC INTERMEDIATE
FIELD OF THE INVENTION
This invention relates to a chemical process for making a pharmaceutically active compound, and specifically to a process for making a biaryl intermediate in the process for making the compound.
SUMMARY OF THE INVENTION
Biaryl chloride 10 is one of two penultimate intermediates in a process for making a pharmaceutically active compound. Biaryl chloride 10 is prepared in a seven step sequence starting from available starting materials. One of the intermediates in the 7-step sequence is prepared in one step, so that the overall preparation of biaryl chloride 10 requires 8 process steps starting from commercially available difluorobromobenzene 1 and trifluoromethylbenzonitrile 6.
Figure imgf000002_0001
Biaryl chloride 10
DETAILED DESCRIPTION OF THE INVENTION
The process for making compound 10 is summarized in Scheme 1 below, and is described in more detail in the subsequent Example. Modifications of this process to obtain similar products, and the products of these process will be readily apparent to one of skill in the art. For example, the process can be modified to produce biaryl halides other than chloride, such as bromide. Similarly, the trifluoromethyl and isopropyl groups can be replaced with other alkyl and fluoroalkyl groups in the synthetic schemes. The methoxyl group can also be replaced with other alkoxy groups in this process by use of a different alkoxy compound in step 1. Scheme 1: Synthesis of Biaryl Chloride 10
STEP 1 STEP 2
STEP 3
Figure imgf000003_0001
(HSiMe2J2O (1 eq.)
STEP 4
TFA (1.3 eq.)
DCE, -100C
STEP 6
[RuCI2(benzene)]2 (0.5 mol%)
PPh3 (1 mol%), KOAc (10 mol%) K3PO4 (2 eq.). NMP, 1200C
Figure imgf000003_0002
Figure imgf000003_0003
eq.)
Figure imgf000003_0004
STEP 8 DMF/SOCI,
Figure imgf000003_0005
Example
The Example below is provided to illustrate the invention, and should not be construed as limiting the invention. The scope of the invention is defined by the Claims. The product of this invention is a useful synthetic intermediate for making certain CETP inhibitors, such as those described in PCT patent applications WO2007/005572 (published after the priority date of this application), WO2006/014413, and WO2006/014357.
STEP 1: Methoxylation
Methoxylation of bromodifluorobenzene 1 is highly regioselective when THF is the solvent. Using the conditions described below, the reaction typically yields an 18/1 ratio of product 2 along with 0.7A% (Assay%) of a dimethoxylated impurity. Other combinations of solvent and temperature and other methoxide salts may also be suitable in this sequence.
Figure imgf000004_0001
MW: 192.99 MW: 205.02
A 5OL round bottom flask (RBF) equipped with an overhead stirrer, a nitrogen inlet, a temperature probe and a condenser was charged with l-bromo-2,4-difluorobenzene 1 (3780 g) followed by THF (14 L) and KOMe (95 wt%, 1587.6g), and then rinsed with 1.1 L of THF. The reaction mixture was heated to 65 - 68 0C over 30 minutes and stirred at that temperature for 4 hr. A second portion of KOMe was then added (144.4 g), and the reaction was stirred for an additional 2 hr. The reaction mixture was cooled to 15 0C and was transferred into a 50 L extractor containing 13.1 L of water. The reaction flask was rinsed with water (2 L) and methyl t-butyl ether (MTBE) (15 L). The layers were cut and the organic layer was washed twice with water (2 x 15 L). The organic layer was concentrated under vacuum (10-20 mmHg, 30 0C) followed by azeotropic removal of water with THF (8 L) (10-20 mmHg, 30 0C). The crude residue was distilled under reduced pressure (90 0C, 3 torr) to yield anisole 2 as a colorless oil.
1H NMR (500 MHz, acetone-ofe) δ 7.58 (dd, IH, Jx = 6.2 Hz, J2 = 8.8 Hz), 6.95 (dd, IH, J1 = 2.8 Hz, J2 = 10.9 Hz), 6.72 (td, IH, J1 = 2.8 Hz, J2 = 8.4 Hz), 3.94 (s, 3H).
STEP 2: Acvlation
Figure imgf000005_0001
Molecular Weight: 205.02
Figure imgf000005_0002
A 50L round bottom flask (RBF) equipped with an overhead stirrer, a nitrogen inlet and a temperature probe was charged with anisole 2 (1748.4g) followed by 1,2- dichloroethane (DCE) (19 L). The solution was then cooled to 00C and AlCl3 (3216.9 g) was added in increments such that the internal temperature did not rise above 60C. Acetyl chloride (1748.4 g) was then added dropwise over the course of 40 minutes with cooling to maintain the internal temperature below 10 0C. The reaction mixture was aged for 0.5 hour at 00C. At this time HPLC showed no more starting material.
The batch was transferred into a 100 L extractor containing H2O (25 L) and
EtOAc (40 L) at 0 0C at a rate such that the internal temperature remained below 20 0C. The batch was stirred for 10 min and the bottom aqueous layer was cut away. The organic layer was washed with IN HCl (20 L) and the layers were cut (note: the organic layer is at the bottom at this stage). The organic layer was then washed with saturated NaHCθ3 (20 L) and the layers were cut. The organic layer was finally washed with half saturated brine (5 L brine + 5 L H2O), and the top aqueous layer was cut away.
The organic layer was then transferred through an inline filter (Polycap™ 75 HD, Whatman Inc.) into a 50 L RBF and concentrated under vacuum (30 mmHg, 300C) to a final volume of ~1 IL, and the solvent was switched to hexanes (74 L) at this volume. The resulting suspension was stirred —30 min at room temperature and 45 min at 00C.
The slurry was filtered through a filter pot, and the solid obtained was washed with cold hexanes (00C, 10 L) The solid was dried overnight under vacuum and a nitrogen sweep to give acetophenone 3 as white needles.
1H NMR (400 MHz, CDCl3) δ 8.12 (d, J= 7.9 Hz, IH), 6.65 (d, J= 12.5 Hz, IH), 3.96 (s, 3H), 2.60 (d, J = 5.2 Hz, 3H); HRMS ESI (m I z): [M+H]+ calcd for C9H9O2FBr, 246.9762; found 246.9764.
STEP 3: Grignard addition Carbinol 4 is obtained by addition of methylmagnesium chloride (bromide and iodide can also be used). The reaction also proceeds with trimethylaluminum (AlMβ3) in DCE/heptane.
Figure imgf000006_0001
Molecular Weight: 247.06 Molecular Weight: 263.1
A IOOL RBF equipped with an overhead stirrer, a nitrogen inlet and a temperature probe was charged with MeMgCl (3.13M in THF, 10.5 L) and cooled to -10 0C. Then, a solution of acetophenone 3 (4112.7 g) in THF (23.5 L) was added over the course of 3 hours so that the internal temperature did not rise above 4 0C. The reaction mixture was aged for 0.5 hour at 00C. At this time HPLC showed no more starting material.
2N HCl (24 L) was added dropwise via a dropping funnel into the reaction mixture (batch was cooled to -100C) so that the internal temperature would stay <20°C (caution: very exothermic). The mixture was then transferred into a 100 L extractor containing EtOAc (30 L). The batch was stirred ~ 10 min and the bottom aqueous layer was cut away. The organic layer was then successively washed with brine (10 L) and a solution of half saturated brine (5 L brine + 5 L H2O). The organic layer was transferred into a 100 L RBF and concentrated under vacuum (10-30 mmHg, 300C) to a final volume of -17 L, then solvent switched to hexanes (75 L) at this volume.
The resulting slurry was cooled to 0 0C and filtered through a filter pot. The solid obtained was washed with cold hexanes (4 L) and dried overnight under vacuum with nitrogen sweep to give carbinol 4 as a white solid.
1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 8.7 Hz, IH), 6.64 (d, J= 13.2 Hz, IH), 3.89 (s, 3H), 1.99 (s, IH)5 1.63 (s, 6H); HRMS ESI (m I z): [M-H2O]+ calcd for Ci0H11OFBr, 244.9968; found 244.9972.
STEP 4: Silane reduction
Figure imgf000007_0001
Molecular Weight: 247.1 Molecular Weight: 263.1
A 5OL RBF equipped with an overhead stirrer, a nitrogen inlet and a temperature probe was charged with tetramethyl disiloxane (2.7 L, 15.50 mole) and DCE (10 L), cooled to -20 0C, and then TFA (1.5 L, 20.19 mole) was added. Then, a solution of carbinol 4 (4074 g, 15.48 mole) in DCE (14 L) was added dropwise over the course of 2-3 hours so that the internal temperature stayed below -5 0C. Temperatures above 5 0C caused increases in impurities. The reaction mixture was aged for 15 min. at -100C. At this time HPLC showed no more starting material.
The batch was transferred into a 100 L extractor containing 16.8 Kg of saturated NaHCCh, stirred for 5 min, and the layers were cut. The bottom organic layer was washed twice with saturated
NaHCO3 (12.1 Kg and 8.8 Kg) and finally with brine (17 Kg). The bottom organic layer was then transferred to a 50 L RBF and concentrated under vacuum (5 mmHg, 40 0C). The residue was then distilled at 90-100 0C under full vacuum (1 torr) to give bromoanisole 5 as a colorless liquid which is contaminated with 5-10% of residual siloxanes. The siloxanes are carried to the next step.
1H NMR (400 MHz, CDCl3) δ 7.40 (d, J= 7.9 Hz, IH), 6.63 (d, J= 11.8 Hz, IH), 3.89 (s, 3H), 3.17 (sept, J= 6.9 Hz, IH), 1.25 (d, J= 6.9 Hz, 6H).
STEP 5: Oxazoline formation
Figure imgf000007_0002
Molecular Weight: 171.12 Molecular Weight: 215.17
A 2OL RBF equipped with an overhead stirrer, a nitrogen inlet, a temperature probe and a condenser was charged with the benzonitrile 6 (3930 g), followed by ethanolamine (3041 mL), CaCl2 (382.4 g) and xylenes (1965 mL). The reaction mixture was heated to 125 0C over 45 min and stirred at this temperature for 17 hr. Then the reaction mixture was allowed to cool to about 800C, and toluene (1965 mL) was added before cooling the reaction mixture to room temperature. The crude reaction mixture was then transferred into a 100 L extractor containing 39 L of 0.1 M KH2PO4. The reaction flask was rinsed with MTBE (8 L) and water (4 L). Heptane (28 L) was added to the extractor and the layers were cut. The aqueous layer was back extracted with a mixture of MTBE (10 L) and heptane (10 L), and then the combined organic layers were washed twice with water (2 x 20 L). The organic was concentrated under vacuum (35 0C to 700C, 30-5 mmHg). The crude residue was distilled under reduced pressure (1100C at 1 - 3 torr) to yield oxazoline 7 as a colorless oil.
1H NMR (500 MHz, acetone-^) δ 8.21 (bs, 2H), 7.90 (d, IH, J = 7.8 Hz), 7.75 (t, IH, J = 7.9 Hz), 4.51 (t, 2H, J= 9.6 Hz), 4.06 (t, 2H, J= 9.5 Hz).
STEP 6 : Ru CH-activation coupling
Ruthenium-catalyzed cross coupling reactions of aryl oxazolines with aryl bomides were first described in a publication by Shuichi Oi et al, J. Org. Chem., 2005, 70, 3113-3119.
The ruthenium-catalyzed CH-activation cross-coupling reaction described below gives a good yield of product using NMP (N-methyl pyrrol idinone) as solvent. It has been observed that as the amount of catalyst is reduced to less than 1 mole%, the reaction proceeds reproducibly only with NMP that contains greater than 0.5 volume% of gamma-butyrolactone impurity.
The use of 10 mol% of potassium acetate (AcOK) allows Ru catalyst loading to be reduced to 0.5 mol%, regardless of the amount of gamma-butyrolactone in the NMP, giving complete conversion in a reproducible fashion. The reaction appears to go to completion at 0.25 mol% of Ru dimer. Either "RuGb benzene" or "RuCb cymene" dimer can be used. Other Ru (II) complexes may also be suitable. All solvents and reagents have to be thoroughly degassed with nitrogen prior to catalyst addition.
Mole
Figure imgf000008_0001
cular Weight: 215.17
Molecular Weight: 381.36
A 50L RBF equipped with an overhead stirrer, a nitrogen inlet and a temperature probe was charged with oxazoline 7 (2755.5 g) followed by anisole 5 (3065.7 g) and NMP (10 L pre- degassed by bubbling nitrogen for 60 min). The reaction after mixing was degassed by bubbling nitrogen for an additional 30 minutes. Then K3PO4 (4842.1 g) and KOAc (112.5 g) were charged, followed by 2 L of degassed NMP (rinse). This suspension was degassed for an additional 60 minutes. The reaction mixture was then heated to 130 0C.
A 5L RBF was charged with degassed NMP (2 L) and triphenylphosphine (29.92 g), and then was degassed by bubbling nitrogen for 30 minutes at rt. The ruthenium complex dimer (28.5 g) was then added, and this solution was degassed for an additional 30 minutes at rt.
When the 5OL RBF reaction mixture reached 130 0C, half of the ruthenium solution (1 L) was transferred. The reaction temperature was lowered to 110 0C, and the reaction was stirred at this temperature for 2 hr before the addition of the second half of the ruthenium catalyst. The reaction mixture was then stirred at this temperature for 7 hr, and was then cooled to room temperature.
The product was precipitated by adding water (17 L) slowly over 2.5 hr while maintaining the temperature below 25 0C. The resulting slurry was filtered through a filter pot, and the reaction flask and the resulting solid were rinsed with NMPrwater (1 : 1.5, 15 L), followed by a water rinse (40 L). The solid was then dried under vacuum with a flow of nitrogen. Biaryl oxazoline 8 was obtained as a dark brown solid.
1H NMR (500 MHz, acetone-rf6) δ 8.13 (d, IH, J = 1.4 Hz), 7.87 (dd, IH, J, = 1.5 Hz, J2 = 8.1 Hz), 7.61 (d, IH3 J= 8.1 Hz), 7.18 (d, IH, J= 8.7 Hz)3 6.81 (d, IH, J = 12.5 Hz), 4.22 (t, 2H, J= 9.6 Hz), 3.88 (t, 2H, J = 9.5 Hz), 3.77 (s, 3H), 3.22 (sept, IH, J= 6.9 Hz), 1.27 (d, 6H, J = 6.9 Hz).
STEP 7 ; Oxazoline activation/reduction
Oxazoline activation/reduction is a 2-step one-pot process. Activation of biaryl oxazoline 8 with methyl chloroformate leads to the activated intermediate 9a, which is subsequently reduced to alcohol 9 by using sodium borohydride in water (Scheme T). The reduction can also be done with lithium borohydride with MeOH as solvent, and also with other borohydride reducing agents.
Scheme 2: Activation/reduction path CICO2Me NaBhVH2O
Figure imgf000010_0001
Figure imgf000010_0002
Figure imgf000010_0003
For the activation step, the amount of residual KF from earlier steps has to be below 500ppm before addition of methyl chloroformate.
Figure imgf000010_0004
Molecular Weight: 381.36 Molecular Weight: 342.33
A 10OL RBF equipped with an overhead stirrer, a nitrogen inlet, a temperature probe and a condenser was charged with biaryl oxazoline 8 (4163 g) and THF (11.6 L). Then, diisopropyl ethyl amine (DIPEA, 180 mL) followed by methyl chloroformate (940 mL) were added at rt, and the resulting mixture was heated to 62°C for 45 minutes. HPLC showed complete conversion of 8 to the activated intermediate. The reaction mixture was then cooled to 0"C, and NaBH4 (1152 g) was added in one portion followed by slow addition of water (3.9 L) over 55 minutes while maintaining the internal temperature below 22°C. The reaction mixture was aged at rt for 17h. HPLC showed complete conversion to biaryl alcohol 9.
The reaction mixture was cooled to 0°C, and 3.1N HCl (9.8 L) was added dropwise over Ih while maintaining the temperature between 0 and 4°C. The reaction mixture was warmed to rt, and MeOH (7.8 L) was added. The mixture was batch concentrated under reduced pressure (20 ramHg, 25°C) to a volume of 24 L. Then MeOH (15.5 L) was added, and the batch was seeded with crystalline product from earlier batches (97 g). The product crystallizes spontaneously, if seed crystals are not available. The slurry was aged at rt for Ih, and water (20 L) was added slowly over 1 h. The slurry was filtered through a filter pot, and the cake was rinsed with MeOH/water (1 : 1 , 8 L) followed by water (16 L). The cake was dried under vacuum at rt with nitrogen sweep over 2 days to give crude biaryl alcohol.
DARCO treatment
A IOOL RBF equipped with an overhead stirrer, a nitrogen inlet and a temperature probe was charged with crude 92 wt% biaryl alcohol 9 (3637.23g), MTBE (23.4 L), heptane (10 L) and finally DARCO KB-G (1673 g). The slurry was stirred at rt for 2h. DARCO was then removed by filtration on a pad of solka-floc and rinsed with MTBE/heptane (70:30, 39 L). The combined filtrates were batch concentrated into a IOOL RBF under reduced pressure (20 mitiHg, 40°C) to a final volume of 3OL, and solvent was switched to heptane (66 L).
The resulting slurry was aged overnight at rt and was then cooled to -15βC for 2h. The slurry was filtered through a filter pot and the cake was washed with cold heptane (-15"C, 20L). The cake was dried under vacuum with nitrogen overnight at rt to give pure biaryl alcohol 9 as a white powder with a residual Ru content of 25 ppm.
1H NMR (500 MHz, acetone-^) δ 7.96 (s, IH), 7.60 (d, IH, J = 7 .0 Hz), 7.33 (d, IH, J= 7.9 Hz), 7.10 (d, IH, J= 8.7 Hz), 6.87 (d, IH, J = 12.5 Hz), 4.47 (bs, 2H), 4.31 (t, IH, J= 5.6 Hz), 3.76 (s, 3H), 3.19 (sept, IH, J= 6.9 Hz), 1.24 (d, 6H, J= 6.9 Hz).
STEP 8: chlorination
Figure imgf000011_0001
Molecular Weight: 342.33 Molecular Weight: 360.77
Thionyl chloride (940ml) was added to a solution of biaryl compound 9 (3.4 kg) in DMF (17L) which was maintained at 100C. The mixture was warmed to room temperature. The mixture was aged until >99.8% conversion was measured by HPLQ. Water (3.4 L) was then added. Seed crystals (lwt%) were added, and the mixture was aged for 30 min more before slowly adding 5.1 L of additional water over ~lhr. The solid was filtered and washed first with 20 L 1:1 DMF:water and then 3x 2OL water. The solid product 10 was dried at 20°C until <0.1wt% water remained. 1H NMR (400 MHz, CDCl3) δ 7.86 (s, IH), 7.63 (d, J = 8.0 Hz, IH), 7.37 (d, J = 8.0 Hz, IH), 7.11 (d, J = 8.6 Hz, IH), 6.70 (d, J = 12 Hz, IH), 4.52 (d, J = 11.0 Hz, IH), 4.40 (d, J= 11.0 Hz, IH), 3.76 (s, 3H), 3.25 (sept, J= 6.9 Hz, IH), 1.28 (d, J= 6.9 Hz1 6H).

Claims

WHAT IS CLAIMED IS:
1. A method of synthesizing compound 10:
Figure imgf000013_0001
comprising the steps of:
(1) coupling compounds 5 and 7 using a transition metal catalyst to yield compound 8:
Figure imgf000013_0002
and (2) subsequently converting compound 8 to compound 10.
2. A method of synthesizing compound 8, comprising the step of coupling compounds 5 and 7 using a transition metal catalyst.
3. The method of Claim 1 or Claim 2, wherein said transition metal catalyst comprises Ru.
4. The method of Claim 3, wherein said transition metal catalyst comprises a soluble Ru(II) catalyst.
5. The method of Claim 3, wherein said transition metal catalyst is selected from [RuCl2(benzene)]2 and [RuCl2(cymene)]2-
PCT/US2007/011777 2006-05-19 2007-05-16 Synthesis of a biaryl synthetic intermediate WO2007136672A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80192506P 2006-05-19 2006-05-19
US60/801,925 2006-05-19

Publications (2)

Publication Number Publication Date
WO2007136672A2 true WO2007136672A2 (en) 2007-11-29
WO2007136672A3 WO2007136672A3 (en) 2008-04-03

Family

ID=38723817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/011777 WO2007136672A2 (en) 2006-05-19 2007-05-16 Synthesis of a biaryl synthetic intermediate

Country Status (1)

Country Link
WO (1) WO2007136672A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2468736A1 (en) 2010-12-23 2012-06-27 LEK Pharmaceuticals d.d. Synthesis of intermediates for preparing anacetrapib and derivates thereof
EP2468735A1 (en) 2010-12-23 2012-06-27 LEK Pharmaceuticals d.d. Synthesis of intermediates for preparing anacetrapib and derivates thereof
CN102603499A (en) * 2012-03-01 2012-07-25 南京药石药物研发有限公司 Synthetic method of 1-bromo-4-fluorin-5-isopropyl-2-metoxybenzene
WO2013091696A1 (en) 2011-12-21 2013-06-27 Lek Pharmaceuticals D.D. Synthesis of intermediates for preparing anacetrapib and derivatives thereof
CN104402684A (en) * 2014-11-27 2015-03-11 广东东阳光药业有限公司 Method for preparing anacetrapib intermediate
EP2891650A4 (en) * 2012-08-31 2016-01-13 Api Corp Method for producing biaryl compound
CN106083536A (en) * 2016-06-14 2016-11-09 浙江永太科技股份有限公司 A kind of preparation method of the bent key intermediate in Ansai
US10624952B2 (en) 2007-03-27 2020-04-21 Cardiovascular Biotherapeutics, Inc. Systems and methods for angiogenic treatment in wound healing

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014357A1 (en) * 2004-07-02 2006-02-09 Merck & Co., Inc. Cetp inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014357A1 (en) * 2004-07-02 2006-02-09 Merck & Co., Inc. Cetp inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MEYER A I ET AL: "OXAZOLINES.XI.SYNTHESIS OF FUNCTIONALIZED AROMATIC AND ALIPHATIC ACIDS. A USEFUL PROTECTING GROUP FOR CARBOXYLIC ACIDS AGAINST GRIGNARD AND HYDRIDE REAGENTS" JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 39, no. 18, 1974, pages 2787-2793, XP000999886 ISSN: 0022-3263 *
MICHAEL REUMAN AND A.I. MEYERS: "The Synthetic Utility of Oxazolines in Aromatic Substitution" TETRAHEDRON, vol. 41, no. 5, 1985, pages 837-860, XP002465471 *
OI S ET AL: "Ortho-selective direct cross-coupling reaction of 2-aryloxazolines and 2-arylimidazolines with aryl and alkenyn halides catalyzed by ruthenium complexes" JOURNAL OF ORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 70, no. 8, 2005, pages 3113-3119, XP003015579 ISSN: 0022-3263 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10624952B2 (en) 2007-03-27 2020-04-21 Cardiovascular Biotherapeutics, Inc. Systems and methods for angiogenic treatment in wound healing
EP2468736A1 (en) 2010-12-23 2012-06-27 LEK Pharmaceuticals d.d. Synthesis of intermediates for preparing anacetrapib and derivates thereof
EP2468735A1 (en) 2010-12-23 2012-06-27 LEK Pharmaceuticals d.d. Synthesis of intermediates for preparing anacetrapib and derivates thereof
WO2012085133A1 (en) 2010-12-23 2012-06-28 Lek Pharmaceuticals D.D. Synthesis of intermediates for preparing anacetrapib and derivatives thereof
WO2013091696A1 (en) 2011-12-21 2013-06-27 Lek Pharmaceuticals D.D. Synthesis of intermediates for preparing anacetrapib and derivatives thereof
CN102603499A (en) * 2012-03-01 2012-07-25 南京药石药物研发有限公司 Synthetic method of 1-bromo-4-fluorin-5-isopropyl-2-metoxybenzene
EP2891650A4 (en) * 2012-08-31 2016-01-13 Api Corp Method for producing biaryl compound
US9624181B2 (en) 2012-08-31 2017-04-18 Api Corporation Method for producing biaryl compound
CN104402684A (en) * 2014-11-27 2015-03-11 广东东阳光药业有限公司 Method for preparing anacetrapib intermediate
CN104402684B (en) * 2014-11-27 2016-09-14 广东东阳光药业有限公司 The method of the bent intermediate in preparation Ansai
CN106083536A (en) * 2016-06-14 2016-11-09 浙江永太科技股份有限公司 A kind of preparation method of the bent key intermediate in Ansai
CN106083536B (en) * 2016-06-14 2018-10-30 浙江永太科技股份有限公司 A kind of preparation method of Ansai Qu key intermediate

Also Published As

Publication number Publication date
WO2007136672A3 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
WO2007136672A2 (en) Synthesis of a biaryl synthetic intermediate
CN103384663B (en) For the preparation of the synthesis of the intermediate of bent of Ansai and derivative thereof
JP2024509797A (en) Synthesis of omecamtibumecarbil
TW202402770A (en) Process for preparing organotin compounds
JP2009522227A (en) Epoxide intermediates in the synthesis of Tamiflu
WO2023235416A1 (en) Compositions and related methods of alkyltintrihalides
HUE032621T2 (en) Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1h-pyrazol-3-ylamine
CN108395423B (en) Synthesis method of 2-benzylidene tetrahydrothiophene derivative
JPH11501313A (en) Catalytic enantioselective synthesis of spiro-fused azetidinones
CN117550960A (en) Process for preparing 1- (3, 5-dichloro-4-fluoro-phenyl) -2, 2-trifluoro-ethanone
DK2803659T3 (en) PROCEDURE FOR SYNTHESIS OF 3,4-DIMETHOXY-BICYCLO [4.2.0] OCTA-1,3,5-TRIEN-7-CARBONITRIL AND USE FOR SYNTHESIS OF IVABRADIN AND ADDED SALTS THEREOF WITH A PHARMACEUTICAL ACCEPTABLE
JPH0794450B2 (en) Process for producing substituted 1,3-dioxolan-2-one derivative
WO2016115962A1 (en) Preparation method for nebivolol intermediate and preparation method for nebivolol
JP5448572B2 (en) Acetyl compound, method for producing the acetyl compound, and method for producing a naphthol compound using the acetyl compound
JP4540197B2 (en) (E) Process for producing 3-methyl-2-cyclopentadecenone
JP3844112B2 (en) 3,5,6-Trihydroxyhexanoic acid ammonium salt derivative and method for producing the same
CN107556237B (en) Preparation method of 3- (2-phenethyl) -2-pyridine carboxamide compound
JP4022413B2 (en) Perfluoroalkylacrylic acid multimers and multimer compositions and methods for their production
JP2005097158A (en) Method for producing fluorine-containing organic compound
JP2000273087A (en) Production of asymmetric 2-imidazolidinones
WO2023013757A1 (en) Method for producing alkylsilyloxy substituted benzyl compound
TW202130617A (en) Process for preparing 1,1&#39;-disulfanediylbis(4-fluoro-2-methyl-5-nitrobenzene)
KR20060096427A (en) Process for the preparation of 1-[cyano(phenyl)methyl]-cyclohexanol compounds
JPS5946234A (en) Preparation of optically active alcohol
JPWO2007114223A1 (en) Method for producing carboxylic acid compound

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07809095

Country of ref document: EP

Kind code of ref document: A2